Insider · CIK 0001687318
Charles Sermon
Files at MREO (Mereo BioPharma Group plc). First filing -, latest -.
In brief
Charles Sermon files SEC Form 4 as officer at MREO (Mereo BioPharma Group plc). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Charles Sermon has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 1, 2026 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +315,750 | $0.00 | $0 | 315,750 | Feb 2, 2026 |
| Feb 1, 2026 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +105,250 | $0.00 | $0 | 105,250 | Feb 2, 2026 |
| Feb 1, 2026 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +295,000 | $0.00 | $0 | 295,000 | Feb 2, 2026 |
Questions about Charles Sermon
Answered from the filings on this page, as of the latest one.
Is Charles Sermon buying or selling?
Charles Sermon has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Charles Sermon's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Charles Sermon has 0.
Where does Charles Sermon file Form 4?
Charles Sermon has filed Form 4 at MREO (Mereo BioPharma Group plc) as General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.